31 August 2020>: Database Analysis
Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma
Dehua Zhang 1ACD , Muchun Zhang 2B , Qifu Zhang 3DF , Zhiyi Zhao 3BCF , Yong Nie 1ADE*DOI: 10.12659/MSM.924543
Med Sci Monit 2020; 26:e924543
Table 2 Essential characteristics of the primary PRAD and normal solid tissue with RNA-seq data.
Variables | Total samples (N=550) |
---|---|
Mean±SD | 61.01±6.82 |
Median (range) | 61 (41–78) |
Female | 0 (0.00%) |
Male | 550 (100.00%) |
T2a | 13 (2.36%) |
T2b | 10 (1.82%) |
T2c | 164 (29.82%) |
T3a | 158 (28.72%) |
T3b | 136 (24.73%) |
T4 | 10 (1.82%) |
Unknown | 7 (1.27%) |
Normal solid tissue | 52 (9.46%) |
N0 | 346 (62.91%) |
N1 | 79 (14.36%) |
Unknown | 73 (13.27%) |
Normal solid tissue | 52 (9.46%) |
Adenocarcinoma, NOS | 485 (88.18%) |
Adenocarcinoma with mixed subtypes | 3 (0.54%) |
Infiltrating duct carcinoma, NOS | 9 (1.64%) |
Mucinous adenocarcinoma | 1 (0.18%) |
Normal solid tissue | 52 (9.46%) |
6 | 45 (8.18%) |
7 | 248 (45.09%) |
8 | 64 (11.64%) |
9 | 137 (24.91%) |
10 | 4 (0.72%) |
Normal solid tissue | 52 (9.46%) |
Mean±SD | 1.86±3.39 |
Median (range) | 0.10 (0.01–323.00) |
Unknown | 84 (15.27%) |
Normal solid tissue | 52 (9.46%) |
Primary PRAD | 498 (90.55%) |
Normal solid tissue | 52 (9.46%) |
PRAD – prostate adenocarcinoma; SD – standard deviation; NOS – not otherwise specified; PSA – prostate-specific antigen. |